

Editorial Comment

Impaired Autonomic Function in Patients with Obstructive Sleep Apnea

Masahiko KATO¹⁾

(*Hypertens Res* 2007; 30: 659–660)

Key Words: sleep apnea, sympathetic activity, baroreflex, nitric oxide

There is growing evidence that obstructive sleep apnea syndrome (OSAS) may contribute to the initiation and progression of hypertension and heart failure. OSAS may have direct and deleterious effects on cardiovascular function and structure through several mechanisms, including sympathetic activation, oxidative stress, inflammation, and endothelial dysfunction.

Continuous positive airway pressure (CPAP) treatment prevents airway collapse during inspiratory efforts. Treatment with CPAP results in acute and marked reduction in nocturnal sympathetic nerve traffic (1) and blunts blood pressure surges during sleep (2). Effective long term treatment of OSAS by CPAP has been shown to improve blood pressure control (3–5), neurohumoral factors and cytokines (6).

In an article appearing in this issue of *Hypertension Research* (7), Noda *et al.* studied the effect of long term CPAP therapy on baroreflex dysfunction and endothelial dysfunction in patients with moderate to severe OSAS. Impairment of baroreflex function may be a potential mechanism linking OSAS to an increased risk of hypertension. Furthermore, decreased heart rate variability and increased blood pressure variability might increase the risk of future hypertension and hypertensive end-organ damage.

They evaluated changes of R-R intervals during phase IV of the Valsalva maneuver as a baroreflex function. It may be impossible to quantify the intensity of stimulation by this method. However, this method is very attractive because it is simple and safe, can be performed without sophisticated equipment, and yields reproducible results. The baroreflex sensitivity (BRS) index for phase IV of the Valsalva maneuver, and the Valsalva ratio were both significantly lower in

patients with OSAS compared to controls in their study. Previous studies have reported that increased sympathetic drive during wakefulness and repetitive surges in blood pressure during sleep might reduce BRS or reset the baroreflex function curve to higher levels of pressure (8, 9). These studies may indicate that OSAS is related to autonomic dysfunction.

Successful CPAP therapy improved the BRS index and Valsalva ratio in the present study by Noda *et al.* (7). Therefore, successful CPAP therapy may attenuate sympathetic hyperactivity and hyperresponsiveness to hypoxia. Narkiewicz *et al.* (10) reported that muscle sympathetic nerve activity (MSNA) decreased after 6 months and 1 year of CPAP therapy. Thus CPAP therapy is the most effective therapy for reducing high sympathetic activity in patients with OSAS.

The authors also pointed out an interesting mechanism related to the regulation of sympathetic outflow. Nitric oxide (NO) is implicated in the regulation of sympathetic outflow in the central nervous system (11). The increase in plasma NO_x concentration after one night of CPAP therapy may contribute to the attenuation of sympathetic hyperactivity. Impairment of endothelial function and inhibition of NO production in OSAS may be implicated in the OSAS-related hypertension.

The diagnosis of OSAS is clinically important. Indeed, the most recent JNC guidelines place sleep apnea at the top of the list of causes of secondary hypertension (12). OSAS should be strongly suspected in obese individuals with resistant hypertension, those with the absence of a nocturnal decrease in blood pressure, and those with symptoms suggestive of OSAS (snoring, and excessive daytime somnolence). Additionally, the recognition of OSAS as a disease related to auto-

From the ¹⁾Department of Cardiovascular Medicine, Tottori University, Yonago, Japan.

Address for Reprints: Masahiko Kato, M.D., Ph.D., Department of Cardiovascular Medicine, Tottori University, 36-1 Nishimachi, Yonago, Japan. E-mail: mkato@grape.med.tottori-u.ac.jp

Received April 25, 2007.

onomic dysfunction helps us understand why circulatory and respiratory regulations are impaired in patients with OSAS-related hypertension and heart failure. Sleep apnea therapy by CPAP will be an additional effective treatment for these patients.

To achieve better neural circulatory control, further studies will be required to find more precise and simpler clinical methods to evaluate the severity of autonomic dysfunction in patients with OSAS.

References

1. Somers VK, Dyken ME, Clary MP, Abboud FM: Sympathetic neural mechanisms in obstructive sleep apnea. *J Clin Invest* 1995; **96**: 1897–1904.
2. Ali NJ, Davies RJO, Fleetham JA, Stradling JR: The acute effects of continuous positive airway pressure and oxygen saturation on blood pressure during obstructive sleep apnea. *Chest* 1992; **101**: 1526–1532.
3. Wilcox I, Grunstein RR, Hedner JA, *et al*: Effect of nasal continuous positive airway pressure during sleep on 24-hour blood pressure in obstructive sleep apnea. *Sleep* 1993; **16**: 539–544.
4. Faccenda JF, Mackay TW, Boon NA, Douglas NJ: Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. *Am J Respir Crit Care Med* 2001; **163**: 344–348.
5. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, *et al*: Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnea: a randomized parallel trial. *Lancet* 2002; **359**: 204–210.
6. Yokoe T, Minoguchi K, Matsuo H, *et al*: Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. *Circulation* 2003; **107**: 1129–1134.
7. Noda A, Nakata S, Koike Y, *et al*: Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome. *Hypertens Res* 2007; **30**: 669–676.
8. Narkiewicz K, Pesek CA, Kato M, Phillips BG, Davison DE, Somers VK: Baroreflex control of sympathetic nerve activity and heart rate in obstructive sleep apnea. *Hypertension* 1998; **32**: 1039–1043.
9. Ogawa Y, Kanbayashi T, Saito Y, *et al*: Total sleep deprivation elevates blood pressure through arterial baroreflex resetting: a study with microneurographic technique. *Sleep* 2003; **26**: 986–989.
10. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK: Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. *Circulation* 1999; **100**: 2332–2335.
11. Zhang K, Mayhan WG, Patel KP: Nitric oxide within the paraventricular nucleus mediates changes in renal sympathetic nerve activity. *Am J Physiol* 1997; **273**: 864–872.
12. Chobanian AV, Bakris GL, Black HR, *et al*: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. *JAMA* 2003; **289**: 2560–2571.